CXCR4 and cancer: Bone marrow aspirates from patients following BL-8040 treatment demonstrated an approximately 73% decrease in CXCR4 BL-8040-occupied AML blasts from pre-treatment levels, indicating that the treatment effectively mobilized cancer cells from the bone marrow to the peripheral blood.